- Home
- BTM vs PRQR Comparison
BTM vs PRQR Comparison
Compare BTM & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTM
- PRQR
- Stock Information
- Founded
- BTM 2016
- PRQR 2012
- Country
- BTM United States
- PRQR Netherlands
- Employees
- BTM N/A
- PRQR N/A
- Industry
- BTM Finance: Consumer Services
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- BTM Finance
- PRQR Health Care
- Exchange
- BTM Nasdaq
- PRQR Nasdaq
- Market Cap
- BTM 266.2M
- PRQR 289.7M
- IPO Year
- BTM N/A
- PRQR 2014
- Fundamental
- Price
- BTM $2.66
- PRQR $2.29
- Analyst Decision
- BTM Strong Buy
- PRQR Strong Buy
- Analyst Count
- BTM 2
- PRQR 7
- Target Price
- BTM $6.25
- PRQR $8.14
- AVG Volume (30 Days)
- BTM 1.6M
- PRQR 653.1K
- Earning Date
- BTM 11-13-2025
- PRQR 11-07-2025
- Dividend Yield
- BTM N/A
- PRQR N/A
- EPS Growth
- BTM N/A
- PRQR N/A
- EPS
- BTM 0.12
- PRQR N/A
- Revenue
- BTM $608,432,000.00
- PRQR $20,129,184.00
- Revenue This Year
- BTM $10.81
- PRQR N/A
- Revenue Next Year
- BTM $6.91
- PRQR N/A
- P/E Ratio
- BTM $20.29
- PRQR N/A
- Revenue Growth
- BTM N/A
- PRQR 8.65
- 52 Week Low
- BTM $0.93
- PRQR $1.07
- 52 Week High
- BTM $6.88
- PRQR $4.21
- Technical
- Relative Strength Index (RSI)
- BTM 39.36
- PRQR 40.17
- Support Level
- BTM $2.45
- PRQR $2.61
- Resistance Level
- BTM $2.79
- PRQR $2.81
- Average True Range (ATR)
- BTM 0.15
- PRQR 0.24
- MACD
- BTM 0.01
- PRQR -0.07
- Stochastic Oscillator
- BTM 37.22
- PRQR 1.19
About BTM Bitcoin Depot Inc.
Bitcoin Depot Inc owns and operates the widest network of BTMs across North America where customers can buy and sell Bitcoin. Bitcoin Depot helps power the digital economy for users of cash. It has locations across the U.S. and Canada at, among others, the following types of retailers: Convenience Stores and Gas Station Chains, Pharmacies and Grocers and Mall Operators.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.